Results 41 to 50 of about 67,411 (205)

Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial.

JAMA Oncology, 2022
Importance Capecitabine maintenance therapy improves survival outcomes in various cancer types, but data are limited on the efficacy and safety of capecitabine maintenance therapy in metastatic nasopharyngeal carcinoma (NPC).
Guo-Ying Liu, Wang-Zhong Li, Devin Wang, Hu Liang, X. Lv, Yan-Fang Ye, Chong Zhao, L. Ke, Shu-hui Lv, N. Lu, Wei-Xin Bei, Zhuo-chen Cai, Xi Chen, Chi-Xiong Liang, Xiang Guo, W. Xia, Yan-Qun Xiang   +16 more
semanticscholar   +1 more source

Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. [PDF]

PLoS ONE, 2016
Capecitabine has been investigated in early breast cancer in several studies, but it was undefined that whether it could improve survival. To investigate whether the addition of capecitabine affected survival in patients with early breast cancer, a meta ...
Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin, Xu-Yuan Li   +3 more
doaj   +1 more source

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

Therapeutic Advances in Medical Oncology, 2019
Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking.
Femke M. de Man, G.D. Marijn Veerman, Esther Oomen-de Hoop, Maarten J. Deenen, Didier Meulendijks, Caroline M.P.W. Mandigers, Marcel Soesan, Jan H.M. Schellens, Esther van Meerten, Teun van Gelder, Ron H.J. Mathijssen   +10 more
doaj   +1 more source

The Impact of Capecitabine and Combined Training on BRCA1 Gene Expression in Breast Cancer Induction [PDF]

Journal of Basic Research in Medical Sciences, 2023
Introduction: This study explores the combined effects of concurrent training and capecitabine consumption on breast cancer prevention and therapy, focusing on the modulation of BRCA1 gene expression.
Masoud Shokuhi Niya, Abbas Salehikia, Maryam Banparvari, Hamed Fanaei   +3 more
doaj  

Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma

Frontiers in Oncology, 2022
BackgroundAdding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
Longjiang She, Kun Tian, Jiaqi Han, Weihan Zuo, Zhu Wang, Ning Zhang   +5 more
doaj   +1 more source

Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine

Cancers, 2021
Simple Summary Colorectal cancer (CRC) begins when normal cells turn out of balance, and a tumor is formed in the lining of the colon or rectum. Cytotoxic T-lymphocyte protein 4 (CTLA-4) is a potent molecule that could inhibit T cell activation. Here, we
Afshin Derakhshani, S. Hashemzadeh, Zahra Asadzadeh, Mahdi Abdoli Shadbad, Farnaz Rasibonab, H. Safarpour, V. Jafarlou, Antonio Giovanni Solimando, V. Racanelli, P. Singh, S. Najafi, Darya Javadrashid, O. Brunetti, N. Silvestris, B. Baradaran   +14 more
semanticscholar   +1 more source

Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.

The Lancet Gastroenterology and Hepatology, 2022
BACKGROUND Trifluridine-tipiracil plus bevacizumab has shown efficacy in previous phase 2 studies including patients with unresectable metastatic colorectal cancer.
T. André, A. Falcone, Y. Shparyk, F. Moiseenko, Eduardo Polo-Marques, T. Csöszi, Arinilda Campos-Bragagnoli, G. Liposits, E. Chmielowska, P. Aubel, L. Martin, R. Fougeray, N. Amellal, M. Saunders   +13 more
semanticscholar   +1 more source

Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials

Frontiers in Endocrinology, 2022
Background and ObjectivePrevious studies determined the therapeutic effects of capecitabine-based chemotherapy regimens on early-stage triple-negative breast cancer (TNBC).
Zhiyang Li, Jiehua Zheng, Zeqi Ji, Lingzhi Chen, Jinyao Wu, Juan Zou, Yiyuan Liu, Weixun Lin, Jiehui Cai, Yaokun Chen, Yexi Chen, Hai Lu   +11 more
doaj   +1 more source

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.

European Journal of Cancer, 2022
BACKGROUND An earlier analysis of the PEARL phase III study showed that palbociclib plus endocrine therapy (ET) does not improve progression-free survival (PFS) over capecitabine in aromatase inhibitor-resistant, hormone receptor-positive/human epidermal
Miguel Martín, C. Zielinski, M. Ruíz-Borrego, E. Carrasco, E. Ciruelos, M. Muñoz, B. Bermejo, M. Margelí, T. Csöszi, A. Antón, N. Turner, M. Casas, S. Morales, E. Alba, L. Calvo, J. R. De La Haba-Rodríguez, M. Ramos, L. Murillo, A. Santaballa, J. Alonso-Romero, P. Sánchez-Rovira, M. Corsaro, Xin Huang, C. Thallinger, Z. Kahán, M. Gil-Gil   +25 more
semanticscholar   +1 more source

The Potential Protective Role of Hesperidin Against Capecitabine-Induced Corneal Toxicity in Adult Male Albino Rat. Light and Electron Microscopic Study [PDF]

The Egyptian Journal of Histology, 2017
Background: Capecitabine is a chemotherapeutic agent widely used for the treatment of malignancies. Ocular disorders have been reported with capecitabine therapy.
Walaa Elwan, Amira Kassab
doaj   +1 more source